Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Trends and disparities in influenza and pneumonia associated sepsis mortality among older adults in the United States, 1999-2022: A retrospective population-based study.

Semergen·2026
Same journal

[High-impact ultrashort simulation-based pulmonary ultrasound training for Family Medicine residents: A prospective educational innovation study].

Semergen·2026
Same journal

[Biopsychosocial intervention for chronic non-cancer pain in Primary Care].

Semergen·2026
Same journal

[Underestimation of Glomerular Filtration Rate Obtained with Serum Creatinine-Based Formulas Compared to Those Using Serum Cystatin in Patients with Increased Muscle Mass].

Semergen·2026
Same journal

Exercise in polycystic ovary syndrome: Moving beyond modality equivalence toward mechanism-based prescription.

Semergen·2026
Same journal

Heinz-Lippmann disease: A case of a non-healing wound.

Semergen·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

[Glaucoma: pharmacological implications].

C Rieger-Reyes1, F J Rubio-Galán

  • 1Unidad Docente Medicina de Familia y Comunitaria Sector II, Zaragoza, España. cris.rieger.reyes@gmail.com

Semergen
|March 23, 2013
PubMed
Summary
This summary is machine-generated.

Glaucoma, a leading cause of irreversible blindness, affects 2% of the population, with many undiagnosed. Primary Care physicians need updated knowledge on glaucoma medications and their side effects for optimal patient management.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

Related Experiment Videos

Last Updated: May 13, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

Area of Science:

  • Ophthalmology
  • Pharmacology

Context:

  • Glaucoma is the primary cause of irreversible blindness globally.
  • Prevalence in the country is 2%, with 50% of cases undiagnosed.
  • Primary Care physicians require updated knowledge on glaucoma management.

Purpose:

  • To update Primary Care physicians on glaucoma.
  • To highlight drugs that can trigger or worsen glaucoma.
  • To inform about systemic side effects of glaucoma treatments.

Summary:

  • Physicians must be aware of drugs that can induce or exacerbate glaucoma.
  • Systemic side effects of topical glaucoma medications necessitate physician awareness.
  • Optimizing the risk/benefit ratio in glaucoma pharmacotherapy is crucial.

Impact:

  • Enhances Primary Care physician's ability to manage glaucoma patients effectively.
  • Aims to reduce the risk of iatrogenic glaucoma and manage side effects.
  • Improves therapeutic outcomes by ensuring appropriate drug selection and monitoring.